Kanglin Biotec

15/09/2026

It was a great pleasure to welcome the delegation from Al-Hadbaa Specialized Hospital to China. 🤝 We sincerely appreciate the valuable scientific and medical exchanges throughout the visit and the opportunity to share knowledge and perspectives. We look forward to building on this meaningful exchange and exploring further opportunities for collaboration together.

14/09/2026

Meet Kanglin Biotec at EGY Health 2026!

We’re excited to share that our colleague Mona (tag Mona)will be representing Kanglin Biotec at EGY Health 2026, taking place from 15–17 September in Egypt.

Mona looks forward to meeting healthcare professionals, hospitals, organizations, and partners from Egypt and across the MENA region, and exchanging ideas on:
🧬 Gene therapy & β-thalassaemia care
🏥 International patient access
🤝 Healthcare partnerships & collaboration

Will you be at EGY Health 2026? Come and connect with Mona!
📅 15–17 September 2026
📍 Egypt

We look forward to seeing you there!

09/09/2026

🌟 Connecting Beyond Borders | Kanglin Biotec at “Stars in the Sky – China” 🌟

At Kanglin Biotec, we believe meaningful connections can cross borders — just as innovation can bring new hope and possibilities to patients around the world.

We were delighted to attend “Stars in the Sky – China,” an inspiring exhibition by renowned Egyptian artist Amr Fahmy at the Egyptian Cultural Office in Beijing. 🎨

The exhibition celebrates inspiring figures and the connections between people and cultures. For Kanglin Biotec, it was also a meaningful opportunity to strengthen our friendship and connection with Egypt.

As a company focused on advancing gene therapy, we hope to continue building bridges with patients, healthcare professionals, and partners across the region. 🌍

🌟 فن من مصر، وأمل من الصين
في معرض "نجوم في السماء – الصين"، جمعنا الفن بالعلم، وجمعتنا القاهرة ببكين.
تشرفنا بحضور هذا المعرض الملهم للفنان المصري عمرو فهمي، حيث يحتفل المعرض بالروابط الإنسانية التي تتجاوز الجغرافيا.
في كانغلين بيوتك، نصنع ابتكارًا لا يعرف حدودًا — لنمنح الأمل لمرضى حول العالم عبر العلاج الجيني.
شكرًا لمصر على هذا اللقاء الجميل. وشكرًا للفن على تذكيرنا بأن الأمل لغة مشتركة.

07/09/2026

🤝 A New Step Forward in International Collaboration

On September 1, Kanglin Biotec, together with West China Lecheng Hospital, welcomed international medical experts and representatives to Hainan for an exchange focused on β-thalassemia care, gene therapy and international collaboration.

A key milestone of the event was a partnership signing with an international hospital partner, marking an important step toward deeper collaboration in thalassemia care and exploring new possibilities for international patient access.

🌍 The meeting brought together medical experts and representatives from MENA and Southeast Asia, creating a valuable opportunity to exchange perspectives and explore future cooperation.

We sincerely thank all our partners, experts and guests who joined us in Hainan.

Together, we look forward to creating greater possibilities for people living with β-thalassemia.

14/08/2026

Thank you to everyone who joined our webinar:

“Gene Therapy for Transfusion-Dependent β-Thalassemia in China: A Clinical Framework from Pre-Treatment Assessment through Long-Term Follow-Up.”

We were pleased to connect with participants from 17 countries, including patients, families, healthcare professionals, and members of the wider thalassemia community.

During the webinar, we discussed:

🧬 Innovative biomedical technologies and advanced therapies at West China Lecheng Hospital, Sichuan University

🌍 The patient journey with Kanexthal™, including treatment preparation and international patient support

💬 We also had an engaging Q&A session, with 19 questions from our audience covering treatment, patient preparation, and access to care.

For people living with transfusion-dependent β-thalassemia and their families, understanding available treatment options and knowing where to find reliable information are important steps in making informed decisions.

A big thank you to Prof. Xiang Jin and Mia Mo for sharing their insights, and to everyone who joined us and contributed to the discussion. ❤️

What would you like to know more about when it comes to gene therapy for β-thalassemia?

Let us know in the comments. 👇

12/08/2026

🔔 Reminder: Our webinar is happening tomorrow!

Join us for an expert discussion on gene therapy for Transfusion-Dependent β-Thalassemia (TDT), including patient assessment, treatment journey, and international patient support.

🌍 Upcoming Webinar | Gene Therapy for Transfusion-Dependent β-Thalassemia in China: A Clinical Framework from Pre-Treatment Assessment through Long-Term Follow-up

Kanglin Biotec, in collaboration with West China Lecheng Hospital, is pleased to present the next session in our webinar series.

This English-language webinar will provide patients, families, patient advocacy groups, and healthcare professionals with practical insights into the Kanexthal™ gene therapy journey in China—from initial evaluation and eligibility assessment to treatment and recovery.

🎙 Speakers:

• Prof. Xiang Jin
Professor, West China Hospital, Sichuan University
Head of Project Development Department, West China Lecheng Hospital

• Zhiyue Mia Mo
International Patient Service/Case Manager
International Business Department, Kanglin Biotec

Key topics will include:

• Eligibility for Kanexthal™ gene therapy
• The Kanexthal™ treatment journey
• Facilities and patient support at West China Lecheng Hospital
• Travel support for international patients

📅 Date: Thursday, August 13, 2026
⏰ Time: 20:00–21:00 China Standard Time (UTC+8)
💻 Platform: Zoom
🌐 Language: English

🔗 Register here:
https://forms.cloud.microsoft/r/ZqP09dz8zR

You can also scan the QR code on the poster to register.

For enquiries, please contact: [email protected]

We look forward to welcoming you and connecting with the global thalassemia community.

03/08/2026

🌍 Upcoming Webinar | Gene Therapy for Transfusion-Dependent β-Thalassemia in China: A Clinical Framework from Pre-Treatment Assessment through Long-Term Follow-up

Kanglin Biotec, in collaboration with West China Lecheng Hospital, is pleased to present the next session in our webinar series.

This English-language webinar will provide patients, families, patient advocacy groups, and healthcare professionals with practical insights into the Kanexthal™ gene therapy journey in China—from initial evaluation and eligibility assessment to treatment and recovery.

🎙 Speakers:

• Prof. Xiang Jin
Professor, West China Hospital, Sichuan University
Head of Project Development Department, West China Lecheng Hospital

• Zhiyue Mia Mo
International Patient Service/Case Manager
International Business Department, Kanglin Biotec

Key topics will include:

• Eligibility for Kanexthal™ gene therapy
• The Kanexthal™ treatment journey
• Facilities and patient support at West China Lecheng Hospital
• Travel support for international patients

📅 Date: Thursday, August 13, 2026
⏰ Time: 20:00–21:00 China Standard Time (UTC+8)
💻 Platform: Zoom
🌐 Language: English

🔗 Register here:
https://forms.cloud.microsoft/r/ZqP09dz8zR

You can also scan the QR code on the poster to register.

For enquiries, please contact: [email protected]

We look forward to welcoming you and connecting with the global thalassemia community.

29/07/2026

🚀 Pioneering Accessible Genetic Therapies Across the Asia-Pacific

Kanglin Bio was proud to participate in the Gene Therapy Symposium 2026, organized by the Gene Therapy Society of Singapore (GTSS) on 25th July 2026 at the National University of Singapore (NUS)!

The symposium brought together regional leaders across therapeutic R&D, clinical trial ex*****on, ethics, and scalable manufacturing—a reminder of how rapidly the cell and gene therapy ecosystem is evolving in Singapore and Southeast Asia.

During the symposium, Kanglin Bio was proud to present our Kanexthal™ Global Access Program and engage in high-impact discussions with fellow participants about making advanced therapeutics more accessible. Centered on our regionally approved gene therapy Kanexthal™ (KL003) for transfusion-dependent β-thalassemia, our program focuses on creating structured pathways to help eligible international patients access single-dose curative treatments.

Engaging with regional stakeholders reinforces our commitment to expanding patient access, fostering clinical collaborations, and bridging the gap between groundbreaking innovations and real-world accessibility.

Thank you to the GTSS committee and all participants for an enriching dialogue! 🧬✨

09/07/2026

A milestone in gene therapy manufacturing—and a step forward for patients worldwide. 🧬

On June 30, 2026, Kanglin Biotec officially launched its Gene Therapy Manufacturing Base at Hangzhou Biopharma Town.
This facility represents a transition from clinical-stage development to commercial-scale, GMP-compliant manufacturing.

With this launch, Kanglin Biotec now establishes in-house manufacturing capabilities across the core production chain for cell and gene therapies, including:
🌟Plasmids
🌟Lentiviral vectors
🌟Adeno-associated virus (AAV) vectors
🌟Cell injection formulations

These capabilities are centralized in a single facility, designed and operated in accordance with international GMP standards.

For international patients and their families, this development has practical implications: it supports more predictable supply chains, reduced manufacturing-related delays, and production processes built for regulatory alignment—all essential factors in bringing gene therapies to those in need.

Our commitment remains focused on advancing cell and gene therapy platforms, not only for the Chinese market, but for global patient communities where unmet medical needs persist.

We will continue to share updates on clinical development, regulatory progress, and our efforts to increase access to transformative therapies.

Because every patient deserves a future built on science, quality, and care. 💙

30/06/2026

🌍 Global Collaboration in Action

Last week, we had the honor of hosting a joint delegation of academic institutions from south America and MENA regions for an in-depth visit across our operations in China.

Their journey took them from North Africa and South America to our GMP facility and HQ in Hangzhou, and then to West China Lecheng Hospital in Boao, Hainan—all to see firsthand how Kanexthal™ (KL003) is advancing from research to real-world impact.

In Hainan, we were proud to showcase West China Lecheng Hospital, now officially designated as a Centre of Excellence for Kanexthal™ administration under China's pioneering medical tourism policy. This is more than a milestone for China—it's a replicable model we hope can benefit patients worldwide.

Our conversations went deep:
🔬 Scientific progress and clinical data
🏭 Manufacturing scale-up and quality assurance
💡 Practical strategies to address the heavy burden of Transfusion-Dependent Thalassemia (TDT) in south America, MENA, and beyond.

We believe that collaboration is the bridge between science and accessible care. This visit was a powerful reminder that when experts from different continents come together with a shared mission, patients win.

Looking forward to the next steps in this global journey. 🚀